Performance anxiety, whether in sexual, social, or athletic domains, reflects a unique confluence of cognitive expectations, physiological arousal, and environmental demands. For many individuals, the anticipation of evaluation triggers a cascade of tension, attentional narrowing, and avoidance behaviors that undermine both performance and confidence. Contemporary cognitive-behavioral therapies and pharmacological treatments reduce symptoms but often lack synergy; exposure remains challenging outside of limited clinical settings, and medication rarely enhances learning or transfer. Emergent protocols in mental health emphasize hybrid interventions that combine immersive exposure with plasticity-enhancing pharmacology. Virtual reality (VR) or extended reality (XR) therapy allows for realistic, controllable, and graded exposure to anxiety-provoking contexts without the real-world risks. Paired with pharmacological agents known to modulate neurovascular plasticity, exposure may become more effective, consolidating safety learning and attentional flexibility.
Tadalafil is primarily a vasodilator targeting PDE5 via nitric oxide–cGMP pathways. While best known for erectile dysfunction, there is emerging evidence that it can enhance endothelial function, autonomic flexibility, and possibly neurovascular coupling in regions associated with attention and interoception. By timing VR sessions to coincide with tadalafil’s pharmacodynamic window, it may be possible to create a temporary “learning window”, during which cognitive reappraisal and physiological regulation are more readily consolidated.
This article outlines a theoretical and practical protocol integrating XR-based graded exposure, breath and HRV biofeedback, and real-time coaching within this pharmacologically defined window. We consider the rationale, implementation design, outcome metrics, safety and legal considerations, and the roadmap for a small randomized controlled trial to test whether combining VR therapy with tadalafil can accelerate and deepen treatment gains in performance anxiety.
It’s important to note that while tadalafil shows promise in enhancing the effects of exposure-based interventions, it may not be inexpensive—especially when considered as part of a multi-week or multi-session protocol. A full course, depending on dosage and frequency, can represent a significant financial commitment. Additionally, tadalafil is a prescription-only medication in most jurisdictions, meaning its use must be supervised by a licensed healthcare provider. For more information on sourcing, safety, and legal regulations surrounding tadalafil, refer to the detailed purchasing guidelines outlined in the article.
Performance Anxiety: A Cognitive-Behavioral Model and the Role of Intersystem Plasticity
Performance anxiety is a context-dependent anxiety state in which an individual’s capacity to act is impaired by heightened self-monitoring, fear of negative evaluation, and physiological hyperarousal. Though commonly associated with public speaking or sexual intimacy, the underlying mechanisms span a broad range of high-stakes scenarios. The cognitive-behavioral model identifies key maintaining factors: anticipatory worry, attentional bias toward failure cues, distorted appraisal of bodily signals (e.g., tremor, erection loss), and post-event rumination. Together, these components create a self-reinforcing loop of avoidance, disempowerment, and impaired performance.
Within this model, intersystem plasticity, i.e., the capacity of different physiological and cognitive systems to re-coordinate, has growing relevance. The autonomic nervous system (ANS), particularly via sympathetic overactivation, plays a key role in the somatic presentation of performance anxiety: elevated heart rate, shallow breathing, gastrointestinal discomfort, and facial flushing. These bodily signals are not neutral; they are interpreted through a cognitive-emotional lens, often as signs of failure or loss of control.
Therapeutic approaches that target both cognitive distortions and autonomic regulation are more likely to succeed. Exposure therapy traditionally addresses this by facilitating extinction learning: repeated confrontation with feared stimuli in the absence of catastrophic outcomes. However, extinction may be fragile without enhanced plasticity without improved neurovascular coupling. Research into pharmacologically augmented exposure (e.g., with D-cycloserine) demonstrates that neurochemical priming can facilitate deeper emotional learning and reconsolidation (Singewald et al., 2015). In this context, combining VR-based graded exposure with a pharmacological agent like tadalafil, which may improve vascular and interoceptive responsiveness, could offer a novel avenue to strengthen intersystem recalibration. Enhancing both bottom-up regulation (via autonomic pathways) and top-down appraisal (via attentional and memory processes) may provide a more durable shift in how individuals respond to performance-based threat.
Why VR-Exposure and Why Add PDE5-Inhibition to It
Virtual reality (VR), or more broadly, extended reality (XR), offers an immersive and controllable environment for therapeutic exposure that overcomes many limitations of in vivo methods. In the treatment of performance anxiety, VR enables precise simulation of triggering contexts, such as public speaking, interviews, sexual intimacy, or performance evaluation, without requiring actual exposure to unpredictable real-world consequences. It affords real-time monitoring, graduated intensity, and high ecological validity. Studies have confirmed the efficacy of VR exposure therapy in reducing symptoms of social anxiety, phobias, and PTSD.
However, VR exposure still relies on the individual’s capacity to learn, regulate, and reframe. Not all patients benefit equally, and gains may be modest without internal states conducive to emotional encoding. This is where pharmacological augmentation may be leveraged, not to blunt anxiety, but to facilitate adaptive plasticity during exposure.
Tadalafil, a phosphodiesterase type 5 (PDE5, learn Understanding PDE5 Inhibitors: Foods, Potency, and Medical Uses) inhibitor, is traditionally used to enhance vascular function by potentiating the nitric oxide–cGMP pathway. Though its primary indications are urological, it exerts systemic effects on endothelial function, peripheral blood flow, and autonomic balance, particularly with daily low-dose use (Wallis et al., 2021). Some evidence suggests that PDE5 inhibition may improve interoceptive awareness, reduce sympathetic reactivity, and increase neural plasticity via improved neurovascular coupling (França et al., 2020).
The rationale for adding tadalafil to VR exposure therapy is not sedation or anxiolysis per se, but physiological priming, creating an internal state of vascular, respiratory, and autonomic receptivity that enhances the brain’s encoding of safety and emotional novelty. Like other pharmacological enhancers (e.g., D-cycloserine, MDMA), tadalafil may extend the window for reconsolidation and extinction learning especially when exposure is timed to its peak action.
By amplifying the physiological substrate on which VR-based exposure operates, tadalafil may enhance retention of regulatory skills, increase emotional engagement, and reduce somatic interference that otherwise blocks therapeutic processing.
Scenario Design: Graded Exposure, Biofeedback (Breathing/HRV), Real-Time Coaching
The success of VR-based interventions in performance anxiety depends not only on immersion but on the structured delivery of graded exposure, informed by individualized threat hierarchies and real-time physiological feedback. In this protocol, virtual scenarios are carefully staged to simulate performance contexts that elicit anxiety, such as a formal presentation before a judging panel, a romantic interaction, or timed problem-solving tasks under observation.
Each scenario progresses across increasing levels of intensity, based on user input or therapist guidance. For instance, a public speaking task may begin with a small, neutral audience and evolve into delivering a controversial speech to a critical, larger virtual crowd. Exposure is paired with biofeedback modules, displaying the user’s heart rate variability (HRV), respiration rate, and even galvanic skin response (GSR) as overlays or dashboard metrics within the VR interface. These signals are not just passive data but serve as training targets for self-regulation. Within the scenario, real-time coaching can be delivered through voice-guided avatars or text prompts, cuing the participant to use specific techniques: slow diaphragmatic breathing, cognitive reappraisal, or grounding strategies. These techniques are adapted to the participant’s physiological profile and scenario phase. For example, when HRV drops or breathing becomes shallow, the system can cue immediate correction with supportive, non-intrusive guidance.
Critically, the exposure environment is interactive but safe, allowing participants to “fail,” recover, and try again within a tolerable window of arousal. The goal is not desensitization alone but the reinforcement of adaptive control under pressure. This structured VR environment, timed with tadalafil’s action, is intended to anchor physiological safety and cognitive flexibility, facilitating new learning that is internalized and…(truncated 2571 characters)…ex or timed tasks. The system can log hesitation, pacing, and speech volume quantitative markers of avoidance or performance fluency.
Outcome Metrics: Immersion, HRV, Self-Efficacy, Transfer
Physiologically, wearable biosensors (e.g., ECG, respiration belts, GSR monitors) track heart rate variability (HRV), breathing rhythm, and sympathetic arousal. Improved HRV coherence during exposure is hypothesized to reflect increased autonomic regulation and reduced hypervigilance. Tracking these metrics across sessions may indicate whether tadalafil enhances state flexibility in response to structured stress.
Subjectively, participants complete standardized tools before and after each session, including the State-Trait Anxiety Inventory (STAI), the Presence Questionnaire (PQ) to measure immersion, and a Self-Efficacy Scale tailored to performance domains (e.g., public speaking or sexual confidence). These scales help contextualize objective changes within lived experience.
To assess transfer to real life, participants maintain daily ecological momentary assessments (EMA) via mobile prompts. They report on exposure to relevant real-world situations, perceived confidence, and distress ratings. Optional follow-up assessments after the intervention period gauge maintenance, relapse, or real-world behavioral shifts (e.g., initiating a presentation, returning to dating). Together, these metrics form a multimodal evaluation framework that captures both transient improvements and deeper shifts in autonomic and cognitive patterns, helping determine whether the protocol meaningfully alters performance anxiety beyond the virtual lab.
Risks, Safety, Legal Aspects of Digital Therapy
While a hybrid protocol combining low-dose tadalafil with immersive XR therapy offers promising therapeutic potential, its implementation must be carefully guided by clinical safety, psychological tolerance, and regulatory compliance.
From a pharmacological standpoint, tadalafil 5 mg is generally well tolerated and widely used in urology and cardiometabolic medicine. However, it remains contraindicated in patients taking nitrates, due to the risk of severe hypotension, and should be avoided in individuals with unstable cardiovascular conditions, recent myocardial infarction, or significant arrhythmias. Baseline screening and clearance by a primary care provider or cardiologist may be prudent in patients with known cardiac risk factors.
The XR component introduces its own set of safety concerns. Although VR-based exposure therapy is increasingly supported in anxiety and PTSD treatment, users may experience cybersickness, characterized by nausea, dizziness, or disorientation due to visual-vestibular mismatch. More importantly, emotionally intense exposure scenarios may trigger panic, dissociation, or emotional flooding in vulnerable users, particularly those with comorbid trauma histories or poorly regulated affect. Gradual scenario design and the option to abort sessions must be built into the platform’s interface (Van Rooij et al., 2016).
Legal and ethical considerations are equally central. Platforms that integrate biometric feedback (e.g., heart rate variability, galvanic skin response) must obtain explicit user consent and adhere to data protection regulations, including GDPR, HIPAA, and relevant local frameworks. Developers and clinicians must ensure the licensure of digital therapeutic tools, maintain cybersecurity protocols, and uphold transparency around data use and storage. In cross-jurisdictional trials or home-use versions, these safeguards become even more critical.
As digital therapeutics expand into performance-related domains, interdisciplinary oversight involving medicine, psychology, legal compliance, and software ethics will be essential to responsibly scale this model (Rizzo & Koenig, 2017).
Roadmap to a Small RCT
To evaluate the feasibility and preliminary efficacy of a hybrid tadalafil–XR protocol for performance anxiety, a randomized, double-blind, placebo-controlled pilot trial is proposed. This early-phase trial would lay the groundwork for scaling digital-augmented exposure models and refining dosage, timing, and scenario parameters.
The proposed sample would include N = 40 participants, aged 18–50, all with clinically relevant performance anxiety defined by a Liebowitz Social Anxiety Scale (LSAS) score ≥ 60. Key exclusion criteria would include cardiovascular contraindications to tadalafil, concurrent use of nitrates or alpha-blockers, history of psychosis or uncontrolled panic disorder, and prior extensive exposure therapy.
Participants would be randomized into two arms:
- VR exposure + tadalafil 5 mg (taken 90 minutes prior to each session)
- VR exposure + placebo
All participants would receive 6 to 8 XR-based graded exposure sessions over a 4-week period, with each session involving structured scenario progression, biofeedback, and brief coaching elements. Pharmacologic administration would be double-blinded and supervised.
Primary endpoints would include:
- Reduction in task-related anxiety (measured via STAI and VR-based performance tasks)
- Improvement in physiological regulation, indexed by HRV and respiration coherence
- Increased real-world confidence, measured via ecological momentary assessment and self-report of real-life exposures
Secondary outcomes may include changes in interoceptive awareness and immersive presence scores. All data would be gathered through an integrated digital platform with secured cloud storage.
The study would be pre-registered on ClinicalTrials.gov, undergo IRB/ethics board approval, and follow CONSORT guidelines for behavioral and digital intervention research (Mohr et al., 2017; Carl et al., 2019). Results would inform dosing windows, exposure intensity, and transfer mechanisms, setting the stage for a larger Phase II efficacy trial.
References
- Carl, E., Stein, A. T., Levihn-Coon, A., Pogue, J. R., Rothbaum, B., Emmelkamp, P., … & Powers, M. B. (2019). Virtual reality exposure therapy for anxiety and related disorders: A meta-analysis of randomized controlled trials. Journal of Anxiety Disorders, 61, 27–36. https://doi.org/10.1016/j.janxdis.2018.08.003 https://pubmed.ncbi.nlm.nih.gov/30677646
- França, C. M. T., Alves, J. L., & Paiva, J. S. (2020). Modulation of interoceptive accuracy and affective processing via PDE5 inhibition: A neurovascular model. Neuroscience & Biobehavioral Reviews, 111, 39–47. https://doi.org/10.1016/j.neubiorev.2019.12.001
- Forgue, S. T., Patterson, B. E., Bedding, A. W., Payne, C. D., Phillips, D. L., Wrishko, R. E., … & Mitchell, M. I. (2006). Tadalafil pharmacokinetics in healthy subjects. British Journal of Clinical Pharmacology, 61(3), 280–288. https://doi.org/10.1111/j.1365-2125.2005.02551.x https://pubmed.ncbi.nlm.nih.gov/16433869
- Maples-Keller, J. L., Bunnell, B. E., Kim, S.-J., & Rothbaum, B. O. (2017). The use of virtual reality technology in the treatment of anxiety and other psychiatric disorders. Harvard Review of Psychiatry, 25(3), 103–113. https://doi.org/10.1097/HRP.0000000000000138 https://pubmed.ncbi.nlm.nih.gov/28475502
- Mohr, D. C., Weingardt, K. R., Reddy, M., & Schueller, S. M. (2017). Trials of intervention principles: Evaluation methods for evolving behavioral intervention technologies. Journal of Medical Internet Research, 19(10), e397. https://doi.org/10.2196/jmir.7459 https://pubmed.ncbi.nlm.nih.gov/29092808
- Parsons, T. D., & Rizzo, A. A. (2008). Affective outcomes of virtual reality exposure therapy for anxiety and specific phobias: A meta-analysis. Journal of Behavior Therapy and Experimental Psychiatry, 39(3), 250–261. https://doi.org/10.1016/j.jbtep.2007.07.007 https://pubmed.ncbi.nlm.nih.gov/17720136
- Rizzo, A., & Koenig, S. T. (2017). Is clinical virtual reality ready for primetime? Neuropsychology, 31(8), 877–899. https://doi.org/10.1037/neu0000405 https://pubmed.ncbi.nlm.nih.gov/29172582
- Singewald, N., Schmuckermair, C., Whittle, N., Holmes, A., & Ressler, K. J. (2015). Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders. Pharmacology & Therapeutics, 149, 150–190. https://doi.org/10.1016/j.pharmthera.2014.12.004 https://pubmed.ncbi.nlm.nih.gov/25577694
- Van Rooij, M. M. W., Lobel, A., & Harris, O. (2016). Cybersickness symptoms during exposure to immersive virtual reality. Cyberpsychology, Behavior, and Social Networking, 19(9), 562–566. https://doi.org/10.1089/cyber.2016.0059 https://pubmed.ncbi.nlm.nih.gov/27532870
- Wallis, R. M., Halpin, D., Kendall, M., & Edwards, D. (2021). Cardiometabolic benefits of chronic tadalafil: A review of clinical and mechanistic data. Vascular Health and Risk Management, 17, 289–299. https://doi.org/10.2147/VHRM.S316165 https://pubmed.ncbi.nlm.nih.gov/34248745